Researchers have been excited about this new drug, a groundbreaking dual treatment showing remarkable results in early trials for size reduction . It acts by targeting both pathways : GLP-1 and GIP, https://joshipag043046.targetblogs.com/41081860/this-new-hope-for-size-management